

5. References

1. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *Am J Med.* 1980;69(4):491-7.
2. Esposito A, Criscitiello C, Gelao L, Pravettoni G, Locatelli M, Minchella I, et al. Mechanisms of anorexia-cachexia syndrome and rationale for treatment with selective ghrelin receptor agonist. *Cancer Treat Rev.* 2015;41(9):793-7.
3. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol.* 2011;12(5):489-95.
4. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. *Arch Intern Med.* 1988;148(7):1586-91.
5. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature.* 1999;402(6762):656-60.
6. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. *Nature.* 2001;409(6817):194-8.
7. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschop M, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. *Br J Cancer.* 2008;98(2):300-8.
8. Lundholm K, Gunnebo L, Korner U, Iresjo BM, Engstrom C, Hylander A, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. *Cancer.* 2010;116(8):2044-52.
9. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. *J Clin Endocrinol Metab.* 2004;89(6):2832-6.
10. Currow DC, Abernethy AP. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. *Future Oncol.* 2014;10(5):789-802.
11. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. *Support Care Cancer.* 2013;21(1):129-37.
12. Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. *Lancet Oncol.* 2015;16(1):108-16.
13. Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. *Support Care Cancer.* 2016;24(8):3495-505.
14. Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. *Lancet Oncol.* 2016;17(4):519-31.
15. Nishie K, Yamamoto S, Nagata C, Koizumi T, Hanaoka M. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis. *Lung Cancer.* 2017;112:25-34.
16. Bai Y, Hu Y, Zhao Y, Yu X, Xu J, Hua Z, et al. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. *Support Care Cancer.* 2017;25(5):1651-9.
17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021:n71.
18. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj.* 2019;366:l4898.
19. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.
20. Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). *Cancer.* 2018;124(3):606-16.
21. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. *Ann Oncol.* 2017;28(8):1949-56.
22. Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. *J Clin Oncol.* 2005;23(33):8500-11.
23. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. *J Clin Oncol.* 1993;11(1):152-4.

24. Madeddu C, Macciò A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the management of cancer cachexia. *Expert Opin Pharmacother*. 2009;10(8):1359-66.
25. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. *Cancer*. 1974;33(6):1607-9.

Appendix 1. Database search strategies

5.1. CENTRAL

1. ((cancer* OR tumor* OR "Tumor" OR "Neoplasm*" OR "malignan*" OR "Anorexia*" OR "Cachexia" OR "Carcinoma" OR "Appetite loss" OR "weight loss")) :ti, ab, kw
2. Mesh descriptor: [Neoplasms] explode all trees
3. Mesh descriptor: [Anorexia] explode all trees
4. Mesh descriptor: [Cachexia] explode all trees
5. (#1 or #2 or #3 or #4)
6. (("Anamorelin" OR "Adlumiz")):ti, ab, kw
7. Mesh descriptor: [Ghrelin] explode all trees
8. Mesh descriptor: [Receptors, Ghrelin] explode all trees
9. (#6 or #7 or #8)
10. (#5 and #9)

5.2. Pubmed

1. ("cancer*[Title/Abstract] OR "tumor*[Title/Abstract] OR "Tumour"[Title/Abstract] OR "Neoplasm*[Title/Abstract] OR "Neoplasms"[MeSH Terms] OR "malignan*[Title/Abstract] OR "Anorexia"[MeSH Terms] OR "Anorexia*[Title/Abstract] OR "Cachexia"[Title/Abstract] OR "Cachexia"[MeSH Terms] OR "Carcinoma"[Title/Abstract] OR "Appetite loss"[Title/Abstract] OR "Weight loss"[Text])